Intellex Acquires Expert by Big Village

We're thrilled to announce that Intellex has acquired Expert by Big Village, effective March 22, 2024. This strategic move enhances our capabilities and strengthens our commitment to delivering exceptional solutions to our customers.

Stay tuned for more updates on how this acquisition will benefit our clients and experts.

For inquiries or more information, please contact us at


Expert Details

Biotechnology & Pharmaceuticals: Drug Development, Due Diligence, Strategy, Finance, Market Analysis

ID: 730470 New Jersey, USA

Request Expert

With an MD-PhD, clinical training, ten years of experience analyzing and investing in companies developing drugs, ex[erience
as a CEO of both private and public biotechnology companies, Expert has seen the drug and biotechnology industries from
many angles. As an investor, he focused on companies developing drugs and became a student of clinical trial design,
interpretation of clinical data, and analysis of pharmaceutical end-markets using prescription trends, epidemiological data and
survey research. Indeed, he has twice been invited to speak at the FDA on topics relating to drug development in the
biotechnology industry. As a portfolio manager, Expert bore entirely the consequences of his due diligence process, as an
incorrect assessment of the likelihood of various potential outcomes would result in losses for him and his investors.

Expert founded and became CEO of EnzymeRx in order to gain practical operational experience in drug development, and
was intimately involved in every aspect of the development of pegadricase for gout and tumor lysis syndrome. He directed IND-
enabling preclinical studies, oversaw scale-up transfer of the manufacturing process to a contract manufacturer, wrote several
phase 1 and 2 clinical trial protocols and two INDs, let all regulatory interactions with the FDA including pre-IND and type C
meetings, and was the study director on twoclinical trials. As CEO of Employer, Expert has led the
phase 2 development of a novel cell therapy based on the ex vivo differentiation of mesenchymal stem cells, which are then
administered to ALS patients. This program has featured a multicenter. randomized, double blind, placebo control phase 2 trial.

These experiences give Expert a unique perspective on drug development and companies developing drugs. He is
particularly skilled at assessing drug candidates, understanding end-markets and developing target product profiles and the
clinical development program needed to attain that profile, strategically planning a translational program, and understanding what
investors and partners want and expect to see in evaluating a company or drug candidates.

As a former sell-side and buy-side analyst and long-short portfolio manager, Expert has ten years of experience with
biotechnology and pharmaceutical stocks, including more than seven years as an investor in those industries. As an analyst at
JP Morgan and Citigroup, he developed an extensive financial modeling skill set, which included building not only detailed
models of company financial statements, but market models of important drugs. He is familiar with a wide range of valuation
techniques. As a portfolio manager, Expert focused on fundamental aspects of biotechnology and pharmaceutical stocks,
with a particular interest in companies facing potentially transformative events, including release of phase 3 clinical data, FDA
reviews and approval decisions, patent litigation and new product launches. He has seen a wide variety of capital-raising
structures over his careers, and has participated in PIPEs, registered directs, IPOs and other types of offerings.

As CEO of EnzymeRx, Expert was intimately involved with the development of a pegylated uricase for gout and tumor lysis
syndrome. He developed a detailed knowledge of gout, its treatment and commercial markets, and has a network of key opinion
leaders. Expert has written several clinical trial protocols for uricase in the treatment of gout, and was the study director on
two phase 1 trials conducted in nearly 50 gout patients. He has extensive experience with the manufacture and preclinical and
clinical testing of uricase, and a deep underst

Evaluated a portfolio of oncology drugs being considered as a possible spin-out on behalf of a venture capital fund.Developed extensive materials, clinical development plan and data room on behalf of a biotechnology company seeking a partnership, and supported outlicensing process.Directed financing (venture capital) and partnering (biotechnology companies)efforts for a biotechnology company with a phase 1 drug.Analyzed prescriber surveys and prescription trends in the hepatitis C market in order to build a forecast for a hepatitis C drug.Analyzed phase 2 clinical data for an oncology drug that was being considered as a potential investment.


Year Degree Subject Institution
Year: 1996 Degree: MD-PhD Subject: Medicine and Molecular Pharmacology Institution: Albert Einstein College of Medicine
Year: 1989 Degree: BS Subject: Biology Institution: MIT

Work History

Years Employer Title Department
Years: 2014 to Present Employer: Undisclosed Title: Chief Executive Officer Department:
Manages all corporate functions with a particular involvement in R&D, clinical development, finance and investor relations.
Years Employer Title Department
Years: 2008 to 2014 Employer: Alchimia Partners Title: President And Managing Member Department:
Expert consults for biotechnology and pharmaceutical companies and investors in those companies.
Years Employer Title Department
Years: 2008 to 2010 Employer: EnzymeRx Title: President And Chief Executive Officer Department:
Responsible for all aspects of the drug development program for pegadricase, a pegylated biologic.
Years Employer Title Department
Years: 2005 to 2008 Employer: Pequot Capital Management Title: Vice President And Portfolio Manager Department:
Managed long-short portfolios of biotechnology and pharmaceuticals stocks.
Years Employer Title Department
Years: 2003 to 2005 Employer: Sands Point Partners Title: Analyst Department:
Researched and selected biotechnology and pharmaceutical stocks for trading in healthcare hedge fund.
Years Employer Title Department
Years: 2001 to 2003 Employer: Citigroup Asset Management Title: Vice President Department: Research
Researched and analyzed biotechnology and pharmaceutical stocks for long-only institutional money management platform.
Years Employer Title Department
Years: 1998 to 2001 Employer: JP Morgan Title: Vice President Department: Equity Research
Sell-side large-cap pharmaceuticals analyst.
Years Employer Title Department
Years: 1996 to 1998 Employer: Hospital of the University of Pennsylvania Title: Resident Physician Department: Medicine and Dermatology
Resident physician.

International Experience

Years Country / Region Summary
Years: 2010 to 2011 Country / Region: China Summary: He executed sale of a drug to 3SBio, a Chinese biotechnology company.

Career Accomplishments

Licenses / Certifications
Have held series 7 and 63 and medical license (none active).
Professional Appointments
Has served on the board of Stemline, a private biotechnology company, and the boards of several not-for-profit institutions.
Publications and Patents Summary
He has 20 published articles in the medical and scientific literature and has presented posters at the American Society of Hematology and the American College of Rheumatology annual meetings.

Additional Experience

Expert Witness Experience
Expert has served as an expert witness for the defendants in a pharmaceuticals securities class action; in this capacity he wrote expert and rebuttal reports and was deposed for his testimony. His expertise relates to the analyst and investor interpretation of clinical data and the performance of stocks during and after release of complex information relating to drugs and drug candidates. He has also provided background information to class action lawyers and the SEC in cases relating to disclosure or lack of disclosure of material information by biotechnology companies.
Vendor Selection
Expert has sourced preclinical and clinical CROs for GLP toxicology studies and clinical trials; he has also sourced contract manufacturers for development and production of a biologic.
Marketing Experience
Expert has a long, longitudinal and deep experience in the biotechnology and pharmaceuticals industries. As a close follower of the industry, he has studied drugs and candidate drugs in all commercially important therapeutic classes, has witnessed companies of all sizes successfully execute development strategies and, just as frequently, make disastrous mistakes. Expert has operational experience in running a biotechnology company and in translational drug development, having run multiple preclinical and clinical studies and led all interactions with the FDA.
Other Relevant Experience
He has had substantial experience analyzing intellectual property in an effort to assess patent robustness and potential infringement, and have drafted several patent applications. I have published 20 papers in the scientific and medical literature, presented data at national medical conferences, and designed corporate presentations and electronic data rooms.

Fields of Expertise

Request Expert

Dev Tool:

Request: expert/biotechnology-pharmaceuticals-drug-development-due-diligence-strategy-finance-market-analysis
Matched Rewrite Rule: expert/([^/]+)(?:/([0-9]+))?/?$
Matched Rewrite Query: experts=biotechnology-pharmaceuticals-drug-development-due-diligence-strategy-finance-market-analysis&page=
Loaded Template: single-experts.php